MedTrace Logo

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

NCT06151691 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2023-11-30

No results posted yet for this study

Summary

This trial aims to develop a minimal residual disease (MRD) detection model for predicting recurrence of patients with stage I-II pancreatic ductal adenocarcinoma after surgery and adjuvant therapy, based on cfDNA fragmentation and methylation signal.

Conditions

Interventions

OTHER

Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test

Blood samples of participants meet the inclusion/exclusion criteria will be collected. Pancreatic ductal adenocarcinoma minimal residual disease detection test.

Sponsors & Collaborators

  • Shanghai Weihe Medical Laboratory Co., Ltd.

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-09-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151691 on ClinicalTrials.gov